Research update
Journal of chromatography. A
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Not yet confirmed
11 Oct 2026
Indexed from PubMed
News
Retatrutide Developments
Concise, sourced summaries of the developments that change how retatrutide's clinical and regulatory outlook should be read.
Developments
All developments
Verified FDA, EMA and Eli Lilly source documents, newly indexed peer-reviewed research and approved editorial analysis. Every entry links to its source record.
Source
Research update
Lancet (London, England)
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
BACKGROUND: Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea. We aimed to assess the efficacy and safety of retatrutide in adults with obesity and type 2 diabetes.
10 Oct 2026
Indexed from PubMed
Research update
Lancet (London, England)
Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Not yet confirmed
10 Oct 2026
Indexed from PubMed
Research update
JAMA
Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
This Medical News article discusses the reasons behind the burgeoning black market for 2 unapproved GLP-1 weight loss drugs and the potential risks associated with their use.
9 Oct 2026
Indexed from PubMed
Research update
European journal of pharmacology
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.
Type 2 diabetes (T2DM) and obesity represent a growing global health burden, sharing underlying pathophysiological mechanisms such as impaired insulin signalling and chronic low-grade inflammation.
8 Oct 2026
Indexed from PubMed
Research update
BMJ case reports
Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.
A woman in her mid-20s presented with 5 days of persistent nausea, repeated vomiting, loose stools and markedly reduced oral intake. Blood tests, urinalysis, abdominal ultrasonography and cerebral MRI identified no alternative cause. Symptoms persisted despite intravenous fluids, metoclopramide, ondansetron and domperidone.
7 Oct 2026
Indexed from PubMed
Research update
Behavioural brain research
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, has shown strong metabolic efficacy, but its effects on diabetes-associated cognitive dysfunction remain unclear.
2 Oct 2026
Indexed from PubMed
Research update
BMJ (Clinical research ed.)
Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
Not yet confirmed
1 Oct 2026
Indexed from PubMed
Research update
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation.
1 Oct 2026
Indexed from PubMed
Research update
JCEM case reports
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.
Prader-Willi syndrome (PWS) is a neurogenetic disorder characterized by hyperphagia, severe obesity, and early-onset metabolic complications, in which durable weight loss is rarely achieved.
1 Oct 2026
Indexed from PubMed
Official source updatemedium
Eli Lilly and Company
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity Participants with a baseline BMI of 35 or higher who took retatrutide 12 mg lost up to an
29 Sept 2026
Confirmed against source document
Official source updatehigh
Eli Lilly and Company
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings from ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes, reaffirmed its safety
15 Sept 2026
Confirmed against source document
Research update
Diabetes, obesity & metabolism
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
AIMS: To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). MATERIALS AND METHODS: Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials.
17 Aug 2026
Indexed from PubMed
Official source updatecritical
Eli Lilly and Company
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S.
12 Aug 2026
Confirmed against source document
Official source updatecritical
Eli Lilly and Company
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost
23 Jul 2026
Confirmed against source document
Official source updatehigh
Eli Lilly and Company
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10 th U.S. manufacturing site announced since 2020 INDIANAPOLIS, Jan.
30 Jan 2026
Confirmed against source document
Research update
Rapid communications in mass spectrometry : RCM
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
RATIONALE: Retatrutide (LY3437943) is a novel long-acting triple incretin receptor agonist that targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).
Not yet confirmed
Indexed from PubMed
Weekly Briefing
The Retatrutide Report
The most important retatrutide developments, once a week.
- Clinical trial changes
- New PubMed research
- FDA / EMA regulatory developments
- Eli Lilly announcements
- Major efficacy and safety updates
No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.